Cancer Tubulin Inhibitors Market By Product ( Docetaxel, Trastuzumab Emtansine, Abraxane, Brentuximab Vedotin, Cabazitaxel ), By Application ( Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Ovarian Cancer ), Industry Trends, Estimation & Forecast, 2017 - 2025

April 2018

 Pages: 176

 ERC 9735

Cancer Tubulin Inhibitors Market is expected to grow with a CAGR of xx% during the forecast period of 2018 to 2025.

Tubulin is a globular protein, which polymerizes into α- and β-tubulins acting as a major component of eukaryotic cytoskeleton. Microtubules are extremely important for the execution of cellular activities such as cellular trafficking, mitosis and cell proliferation. However, excessive amplification of mitosis coupled with complicated and abnormal cellular activities can lead to the emergence of cancer developing origins. Tubulin inhibitors such as Docetaxel and Abraxane have been found highly efficient in targeting the taxane and vinca binding sites which avoids further clustering in expansion of cancerous cells. Tubulin inhibitors work by interfering the microtubule dynamics either by inhibiting the polymerization or depolymerization. Tubulin inhibitors are well approved cancer drugs and are being deployed all over the world. Since the last decade, tubulin inhibitors have emerged out as a major cancer therapy and has become a point of focus due to ongoing researches in the field of micro biology. A continuous demand for developing and commercializing a novel and least penetrative mode of chemotherapeutics is propelling the growth of cancer tubulin inhibitors market. Moreover, a high rate of occurrence of breast and prostate cancer is contributing substantially in the increasing demand for tubulin inhibitors. However toxicity and problematic side effects caused by these inhibitors might act as a major hindrance in the growth of the very market.

The report provides detailed qualitative and quantitative analysis of the Cancer Tubulin Inhibitors Market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely type and application in each of the major regions.

Cancer Tubulin Inhibitors Market Player Analysis -

The report presents detailed analysis of major players operating in Cancer Tubulin Inhibitors Market. Few of the include Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, Genentech, Immunogen, Modra Pharmaceuticals, Pierre Fabre, Roche, Sanofi-Aventis, Seattle Genetics, Tocris Bioscience. A detailed coverage on these market players with information on their revenue from Cancer Tubulin Inhibitor business, market share, gross margin and their growth strategies have been provided in the report.

Market Segmentation

Cancer Tubulin Inhibitors market is segmented on the basis of type, application and geography. By type, the market is segmented into Re-locatable and permanent. On the basis of application, the market is categorized as commercial, infrastructural and residential. Geographical coverage has been provided for each of the major regions including North America, Europe, Asia-Pacific, South America and Rest of the World.

Cancer Tubulin Inhibitors Market Segmentation

By Product
   • Docetaxel
   • Trastuzumab Emtansine
   • Abraxane
   • Brentuximab Vedotin
   • Cabazitaxel

By Application
   • Non-Small Cell Lung Cancer
   • Prostate Cancer
   • Breast Cancer
   • Colorectal Cancer
   • Ovarian Cancer

By Geography
   • North America
            o U.S.
            o Canada
            o Mexico
   • Europe
            o U.K.
            o France
            o Germany
            o Italy
            o Spain
            o Rest of Europe
   • Asia-Pacific
            o China
            o Japan
            o India
            o Korea
            o Rest of APAC
   • South America
            o Brazil
            o Rest of South America
   • Rest of the World
            o Middle East
            o Africa

Cancer Tubulin Inhibitors Market Key Players

• Abraxis Biosciences
• Agensys
• Amgen
• Celgene
• Eagle Pharmaceuticals
• Endocyte
• Genentech
• Immunogen
• Modra Pharmaceuticals
• Pierre Fabre
• Roche
• Sanofi-Aventis
• Seattle Genetics
• Tocris Bioscience

Please fill in the form below to Request for Customized Report
  
Your personal details are safe and secured with us. Privacy Policy

To request sample copy of this report, please complete the form below verified and secure

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report. This also includes a 30 minute free analyst discussion post report purchase.

  
Your personal details are safe and secured with us. Privacy Policy

    What Information does this report contain?

    • What was the market size of the Cancer Tubulin Inhibitors Market in 2017 and the expected market size by 2025, along with the growth rate?
    • An in-depth analysis of the current impacting factors, opportunities and challenges/restraints in the market
    • Which are the largest revenue generating products, services or regions and their comparative growth rate?
    • Which technology is in trend and how would it evolve during the forecast period (2017 - 2025)?
    • Which are the leading companies in the Cancer Tubulin Inhibitors Market and their competitive positioning basis their market share, product portfolio, strategic attempts and business focus?

Purchase Options





Offers & Discounts

  • Chapter purchase
  • Historical market data
  • Country level data breakdown
  • Free customization*
  • Discounts for first time
  • Special pricing for
              non-business entities

Customize

  • We offer 20% free customization on every purchase.

Get in touch!

  +91-844-601-6060


  help@esticastresearch.com